Short Courses | Day 1 | Day 2 | Download Brochure 

Thursday, May 20

 12:00 pm Registration

SELECTION CRITERIA FOR BISPECIFIC ANTIBODIES: How Do You Decide When to Use Them and which Is a Better Choice?

1:30 Chairperson’s Opening Remarks

Patrick Baeuerle, Ph.D., CSO & Senior Vice President, R&D, Micromet


Bispecific Antibodies: Developments and Current Perspectives

Roland KontermannRoland Kontermann, Ph.D., Professor, Biomedical Engineering, Institute of Cell Biology & Immunology, University of Stuttgart

The concept of using bispecific antibodies for tumor therapy was developed more then 20 years ago. Initial clinical trials have failed because of low efficacy, severe side effects and immunogenicity of the hybridoma-derived bispecific antibodies. New developments in the field of antibody engineering have led to second-generation bispecific antibodies and a revival of these molecules for tumor therapy.

2:10 Single Chain Immunoglobulins – A New Way to Generate Bispecific Antibodies

Thomas Schirrmann, Ph.D., Senior Scientist, Institute of Biochemistry and Biotechnology, Technische Universität Braunschweig

Single chain immunoglobulins (scIgGs) only require the assembly of two identical polypeptide chains thus promising to facilitate heterologous production, surface display, among others, and opening new ways for the improved generation of bispecific antibodies. The production in mammalian cells resulted in a majority of homodimeric scIgG molecules with high apparent affinity to their antigen. Based on the scIgG and scFv-Fc format we further demonstrate the generation of tetravalent bispecific antibodies which are still being encoded by a single gene.

2:40 Sponsored Presentations (Opportunities Available)

3:10 Networking Refreshment Break, Poster and Exhibit Viewing

4:00 Efficient Chemical Approaches to Bispecific Antibodies and Antibodies of High Valency

Carlos F. Barbas III, Ph.D., Kellogg Professor, The Skaggs Institute for Chemical Biology, Department of Chemistry, The Scripps Research Institute

Efficient chemical programming approaches have been developed that provide for versatile and economically viable routes to bispecific antibodies and high-valency therapeutic antibodies. These approaches are further augmented with our development of a new tyrosine ligation reaction for bioconjugation. These approaches are applicable to chemically programmed antibodies, vaccines, and the modification of virtually any therapeutic antibody.

4:30 Chimeric Antigen Receptors Arm T-Cells to Fight Cancer

Hinrich J. Abken, M.D., Professor, Internal Medicine I, University of Cologne

Research into redirecting the cellular immune response against cancer resulted in the development of chimeric antigen receptors which consist of a single-chain antibody fragment, specific to a tumour-associated antigen, fused to a component of the T-cell receptor complex. Upon antigen binding on tumor cells, chimeric antigen receptor primes the engrafted T-cell for anti-tumour activity. Mouse tumor models indicate remarkable efficacy and clinical trials have been initiated.

5:00 Problem Solving Break-Out Sessions

Table 1: Targeting Stem Cells with Bispecific Antibodies

Moderator: Lawrence G. Lum, M.D., DSc, Professor Medicine, Professor of Immunology and Microbiology, Scientific Director of Immunotherapy and BMT, Barbara Ann Karmanos Cancer Institute

• What types of cells can induce regeneration of myocardium? 
• How do we get the cells to the site and remain at the site? 
• What types of functions related to stem cells or other cells can be induced for tissue repair? 
• How can we assess whether infusions of the cells actually repaired cardiac tissue? 

Table 2: Bispecific Antibodies for Tumor Therapy

Moderator: Roland Kontermann, Ph.D., Professor, Biomedical Engineering, Institute of Cell Biology & Immunology, University of Stuttgart


Table 3: Challenges in Developing Bispecific Antibodies

Moderator: To be Announced

6:00 End of Day


Short Courses | Day 1 | Day 2 | Download Brochure

Program Navigation

Phage and Yeast Display of Antibodies and Proteins Engineering Antibodies Antibody Optimization Difficult to Express Proteins Pre-Clinical/Clinical Development Revival of Bispecific Antibodies Immunogenicity of Therapeutic Biologics Protein Aggregation in Biopharmaceutical Products Biotherapeutic Targets

Japan-Flag Korea-Flag China-Simplified-Flag China-Traditional-Flag